Urogen Pharma (NASDAQ:URGN) Receives Consensus Recommendation of "Buy" from Brokerages

Urogen Pharma (NASDAQ:URGN - Get Free Report) has been given a consensus recommendation of "Buy" by the eight ratings firms that are presently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. The average 1 year target price among analysts that have covered the stock in the last year is $32.86.

Several analysts recently commented on the stock. D. Boral Capital reiterated a "buy" rating and issued a $25.00 price target on shares of Urogen Pharma in a research report on Monday, July 7th. Scotiabank reiterated an "outperform" rating on shares of Urogen Pharma in a research report on Friday, June 13th. Guggenheim reiterated a "buy" rating and issued a $30.00 price target (up previously from $15.00) on shares of Urogen Pharma in a research report on Friday, June 13th. The Goldman Sachs Group set a $16.00 price target on shares of Urogen Pharma and gave the company a "neutral" rating in a research report on Friday, June 13th. Finally, HC Wainwright restated a "buy" rating and set a $50.00 price objective on shares of Urogen Pharma in a research report on Tuesday, July 8th.

Insider Activity at Urogen Pharma

In other news, insider Mark Schoenberg sold 5,162 shares of the company's stock in a transaction dated Monday, June 9th. The shares were sold at an average price of $7.37, for a total transaction of $38,043.94. Following the completion of the transaction, the insider owned 153,378 shares in the company, valued at approximately $1,130,395.86. This represents a 3.26% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 5.10% of the company's stock.

Institutional Investors Weigh In On Urogen Pharma

Several institutional investors have recently bought and sold shares of the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in Urogen Pharma by 4.7% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 21,667 shares of the company's stock valued at $231,000 after buying an additional 969 shares in the last quarter. Wellington Management Group LLP lifted its stake in Urogen Pharma by 0.8% during the first quarter. Wellington Management Group LLP now owns 148,078 shares of the company's stock valued at $1,638,000 after buying an additional 1,125 shares in the last quarter. Rhumbline Advisers lifted its stake in Urogen Pharma by 4.3% during the first quarter. Rhumbline Advisers now owns 53,466 shares of the company's stock valued at $591,000 after buying an additional 2,196 shares in the last quarter. MetLife Investment Management LLC lifted its stake in Urogen Pharma by 13.6% during the fourth quarter. MetLife Investment Management LLC now owns 22,766 shares of the company's stock valued at $242,000 after buying an additional 2,727 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its stake in Urogen Pharma by 3.3% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 93,517 shares of the company's stock valued at $996,000 after buying an additional 3,024 shares in the last quarter. Institutional investors and hedge funds own 91.29% of the company's stock.

Urogen Pharma Price Performance

Shares of URGN stock traded down $0.14 during trading on Friday, reaching $15.27. The company's stock had a trading volume of 1,201,133 shares, compared to its average volume of 1,106,603. The company has a market capitalization of $705.47 million, a price-to-earnings ratio of -4.80 and a beta of 1.02. The stock's 50-day moving average price is $10.37 and its 200 day moving average price is $10.50. Urogen Pharma has a 1-year low of $3.42 and a 1-year high of $17.00.

Urogen Pharma (NASDAQ:URGN - Get Free Report) last posted its quarterly earnings results on Monday, May 12th. The company reported ($0.92) EPS for the quarter, missing the consensus estimate of ($0.83) by ($0.09). Urogen Pharma had a negative return on equity of 97,487.15% and a negative net margin of 150.68%. The firm had revenue of $20.25 million for the quarter, compared to analyst estimates of $22.71 million. On average, sell-side analysts anticipate that Urogen Pharma will post -3.12 EPS for the current fiscal year.

Urogen Pharma Company Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.